Policy Tracker · Patient Lens · September 20, 2026
GLP-1 trials now reach cancer patients, sleep apnea and liver disease
Four new studies are testing whether these drugs work far beyond weight loss, and who might get access first.
Key details
- An early-stage trial is testing whether a GLP-1 is safe alongside chemotherapy for metastatic pancreatic, colorectal and liver cancer, because no data exists yet.
- Amgen is recruiting 250 adults with obstructive sleep apnea and obesity for a 52-week Phase 3 trial of maritide.
- The LIVERAGE Phase 3 trial is enrolling people who have MASH liver disease with cirrhosis to test survodutide, which is not approved anywhere.
- Another trial will test tirzepatide in people who did not lose enough weight after bariatric surgery.
4 developments affecting GLP-1 access were tracked on Saturday, September 19, 2026, across 1 category. Each entry links to the full record.
## Research and trials
**[First trial of semaglutide with cancer chemotherapy](/fda/clinical-trial-nct07627191)**. A new early-stage trial will test whether semaglutide is safe to use alongside chemotherapy for certain metastatic cancers.
**[Amgen's new sleep apnea trial: What maritide could mean](/fda/clinical-trial-nct07225686)**. Amgen is recruiting 250 adults with sleep apnea and obesity for a Phase 3 trial of a new GLP-1-type drug called maritide.
**[New GLP-1 drug trial for advanced liver disease now enrolling](/fda/clinical-trial-nct06632457)**. A large Phase 3 trial is now enrolling patients with NASH/MASH liver disease and cirrhosis to test a GLP-1-related drug called survodutide.
**[Mazdutide pancreas trial starts recruiting in late 2026](/fda/clinical-trial-nct07803705)**. A clinical trial testing mazdutide for fatty pancreas is enrolling 194 people starting November 2026; the drug is not yet approved.
By Amanda Bonello